GLP-1s and the High Cost of Providing Health Care

Rising demand for GLP-1 drugs like Ozempic and Wegovy is forcing companies to decide whether to cover, limit, or drop the benefit, with the medications costing employers up to $7,000 per employee annually. Prices are expected to fall once patents on the two dominant suppliers expire and generics enter the market, but until then companies must navigate the tradeoff between cost control and employee health and retention. Yale’s Robert Galvin outlines five strategies executives can use to manage the landscape in the short term.

Raccontata dacbsnews.comtheweek.comindependent.co.ukfortune.comhbr.org